A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations (FURTHER)
Phase 1 – testing safety in a small group of people
Conditions:
Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR or HER2 kinase domain mutations
Sponsor: Arrivent Biopharma Inc.
trial.available_in:
БГ
Overview
Trial status: Authorised
Who can participate
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 32 participants
БГ